Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.

de Man FM, Hussaarts KGAM, de With M, Oomen-de Hoop E, de Bruijn P, van Halteren HK, van der Burg-de Graauw NCHP, Eskens FALM, van Gelder T, van Leeuwen RWF, Mathijssen RHJ.

Clin Pharmacol Ther. 2019 Jun;105(6):1456-1461. doi: 10.1002/cpt.1331. Epub 2019 Feb 10.

2.

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA.

Drugs. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0. Review.

3.

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study.

Koedijk MS, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprengers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemssen FEJA, Méndez Romero A.

BMJ Open. 2018 Oct 15;8(10):e020731. doi: 10.1136/bmjopen-2017-020731.

4.

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.

Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ.

J Surg Oncol. 2018 Nov;118(6):1021-1026. doi: 10.1002/jso.25233. Epub 2018 Sep 27.

5.

Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.

Labeur TA, Ten Cate DWG, Bart Takkenberg R, Azahaf H, van Oijen MGH, van Delden OM, de Man RA, van Vugt JLA, IJzermans JNM, Eskens FALM, Klümpen HJ.

Acta Oncol. 2018 Nov;57(11):1467-1474. doi: 10.1080/0284186X.2018.1479070. Epub 2018 Jun 26.

PMID:
29943624
6.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6.

7.

Tivozanib: a new treatment option for renal cell carcinoma.

Saes L, Eskens FALM.

Drugs Today (Barc). 2017 Nov;53(11):609-618. doi: 10.1358/dot.2017.53.11.2724804. Review.

PMID:
29451277
8.

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.

de Brabander J, Eskens FALM, Korsse SE, Dekker E, Dewint P, van Leerdam ME, van Eeden S, Klümpen HJ.

Oncologist. 2018 Apr;23(4):399-e33. doi: 10.1634/theoncologist.2017-0682. Epub 2018 Jan 25.

9.

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.

Clin Cancer Res. 2018 Feb 15;24(4):766-776. doi: 10.1158/1078-0432.CCR-17-2522. Epub 2017 Dec 12.

10.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

11.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH.

Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

PMID:
27533851
12.

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.

Benson AB 3rd, Kiss I, Bridgewater J, Eskens FA, Sasse C, Vossen S, Chen J, Van Sant C, Ball HA, Keating A, Krivoshik A.

Clin Cancer Res. 2016 Oct 15;22(20):5058-5067. Epub 2016 Jul 11.

13.

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH.

Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8.

PMID:
26345519
14.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.

Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ.

BMC Cancer. 2015 Mar 26;15:180. doi: 10.1186/s12885-015-1199-8.

15.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM.

Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5.

16.

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA.

Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16.

PMID:
25591799
17.

Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.

Hamberg P, Mathijssen RH, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, Sleijfer S, Verweij J, de Jonge MJ.

Cancer Chemother Pharmacol. 2015 Feb;75(2):365-71. doi: 10.1007/s00280-014-2655-x. Epub 2014 Dec 23.

PMID:
25533184
18.

Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment.

Erdmann JI, Eskens FA, Vollmer CM, Kok NF, Groot Koerkamp B, Biermann K, van Eijck CH.

Ann Surg Oncol. 2015 Jul;22(7):2401-7. doi: 10.1245/s10434-014-4267-4. Epub 2014 Dec 12. Review.

PMID:
25503345
19.

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.

J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

20.

Hepatocellular carcinoma: Dutch guideline for surveillance, diagnosis and therapy.

Eskens FA, van Erpecum KJ, de Jong KP, van Delden OM, Klumpen HJ, Verhoef C, Jansen PL, van den Bosch MA, Méndez Romero A, Verheij J, Bloemena E, de Man RA.

Neth J Med. 2014 Jul;72(6):299-304. Review.

21.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V.

Br J Cancer. 2014 Apr 29;110(9):2170-7. doi: 10.1038/bjc.2014.137. Epub 2014 Apr 8.

22.

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept.

Dietvorst MH, Eskens FA.

Biol Ther. 2013;3:25-33. Epub 2013 Feb 28. Review.

23.

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.

Hamberg P, Boers-Sonderen MJ, van der Graaf WT, de Bruijn P, Suttle AB, Eskens FA, Verweij J, van Herpen CM, Sleijfer S.

Br J Cancer. 2014 Feb 18;110(4):888-93. doi: 10.1038/bjc.2013.798. Epub 2013 Dec 24.

24.

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J.

Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27.

25.

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2.

26.

Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers.

Witjes CD, Polak WG, Verhoef C, Eskens FA, Dwarkasing RS, Verheij J, de Man RA, Ijzermans JN.

Dig Surg. 2012;29(6):522-8. doi: 10.1159/000348669. Epub 2013 Mar 27.

27.

Evaluation of patient enrollment in oncology phase I clinical trials.

van der Biessen DA, Cranendonk MA, Schiavon G, van der Holt B, Wiemer EA, Eskens FA, Verweij J, de Jonge MJ, Mathijssen RH.

Oncologist. 2013;18(3):323-9. doi: 10.1634/theoncologist.2012-0334. Epub 2013 Feb 21.

28.

Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).

Haberkorn BC, Eskens FA.

Future Oncol. 2013 Jan;9(1):13-20. doi: 10.2217/fon.12.167. Review.

PMID:
23252559
29.

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor.

Eskens FA, Haberkorn B.

Transl Androl Urol. 2012 Dec;1(4):207-8. doi: 10.3978/j.issn.2223-4683.2012.06.02. No abstract available.

30.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL.

Invest New Drugs. 2013 Apr;31(2):399-408. doi: 10.1007/s10637-012-9890-y. Epub 2012 Nov 17.

31.

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA.

Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.

32.

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J.

Clin Cancer Res. 2011 Nov 15;17(22):7156-63. doi: 10.1158/1078-0432.CCR-11-0411. Epub 2011 Oct 5.

33.

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.

van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP.

Thyroid. 2011 Feb;21(2):197-202. doi: 10.1089/thy.2010.0234.

PMID:
21275767
34.

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.

van Herpen CM, Eskens FA, de Jonge M, Desar I, Hooftman L, Bone EA, Timmer-Bonte JN, Verweij J.

Br J Cancer. 2010 Oct 26;103(9):1362-8. doi: 10.1038/sj.bjc.6605917. Epub 2010 Sep 28.

35.

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.

Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE, Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA.

Br J Cancer. 2010 Sep 28;103(7):987-92. doi: 10.1038/sj.bjc.6605867. Epub 2010 Sep 7.

36.

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.

Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S.

Eur J Cancer. 2010 Dec;46(18):3200-4. doi: 10.1016/j.ejca.2010.07.036. Epub 2010 Aug 18.

PMID:
20727735
37.

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

Steeghs N, Gelderblom H, Wessels J, Eskens FA, de Bont N, Nortier JW, Guchelaar HJ.

Invest New Drugs. 2011 Feb;29(1):137-43. doi: 10.1007/s10637-009-9347-0. Epub 2009 Nov 19.

38.

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.

Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ.

J Clin Oncol. 2009 Oct 20;27(30):5094-101. doi: 10.1200/JCO.2008.21.6655. Epub 2009 Sep 21.

PMID:
19770380
39.

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S.

Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Erratum in: Clin Cancer Res. 2009 Nov 1;15(21):6744.

40.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.

J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.

PMID:
19636022
41.

[Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006].

Dols LF, Verhoef C, Eskens FA, Schouten O, Nonner J, Hop WC, Méndez Romero A, de Man RA, van der Linden E, Dwarkasing RS, IJzermans JN.

Ned Tijdschr Geneeskd. 2009 Mar 14;153(11):490-5. Dutch. No abstract available.

PMID:
19402322
42.

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.

Witjes CD, Verhoef C, Verheul HM, Eskens FA.

Neth J Med. 2009 Mar;67(3):86-90. Review.

43.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, Ter Steeg J, Brandely M, Puozzo Ch, Verweij J.

Eur J Cancer. 2009 Jul;45(10):1764-72. doi: 10.1016/j.ejca.2009.01.026. Epub 2009 Feb 27.

PMID:
19251409
44.

[Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study].

Witjes CD, de Man RA, Eskens FA, Dwarkasing RS, Zondervan PE, Verhoef C, Ijzermans JN.

Ned Tijdschr Geneeskd. 2010;154:A1747. Dutch.

PMID:
20719013
45.

The spliceosome as target for anticancer treatment.

van Alphen RJ, Wiemer EA, Burger H, Eskens FA.

Br J Cancer. 2009 Jan 27;100(2):228-32. doi: 10.1038/sj.bjc.6604801. Epub 2008 Nov 25. Review.

46.

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

Eskens FA, Sleijfer S.

Eur J Cancer. 2008 Nov;44(16):2350-6. doi: 10.1016/j.ejca.2008.07.042. Epub 2008 Sep 11. Review.

PMID:
18789679
47.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.

Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG.

Br J Cancer. 2008 Jan 15;98(1):80-5. Epub 2007 Nov 20.

48.

Trial design for cancer (cell)-specific anticancer therapies.

van Alphen RJ, Verweij J, Eskens FA.

Expert Opin Ther Targets. 2007 Sep;11(9):1137-41.

PMID:
17845141
49.

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR.

Cancer Chemother Pharmacol. 2008 Mar;61(3):435-41. Epub 2007 Apr 18.

PMID:
17440725
50.

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.

van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A.

Br J Cancer. 2007 May 7;96(9):1348-52. Epub 2007 Apr 17.

Supplemental Content

Loading ...
Support Center